How to take Rezlidhia (Olutasidenib)

Rezlidhia (olutasidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of patients with relapsed or refractory acute myeloid leukemia who are predisposed to IDH1 mutations as detected by an FDA-approved test. Rezlidhia belongs to a class of drugs called IDH1 inhibitors. It works by slowing or stopping the growth of cancer cells.

Rezlidhia is an oral capsule with a recommended dose of 150 mg taken orally twice daily until disease progression or unacceptable toxicity occurs. Do not take 2 doses within 8 hours, take it on an empty stomach at least 1 hour before or 2 hours after a meal. For patients without disease progression or unacceptable toxicity, treat for at least 6 months to allow time for clinical response. Doctors may reduce the dose of Rezlidhia or temporarily or permanently stop treatment with Rezlidhia based on the patient's response to treatment or any side effects the patient experiences. In patients with acute myeloid leukemia (AML) given the recommended dose, the steady-state daily area under the plasma concentration versus time curve (AUC0-12-h, ss) of Rezlidhia was 43,050 ng⋅h/mL, and its steady-state Cmax was 3,573 ng/mL. The Cmax and AUC of Rezlidhia increase in a less than proportional manner between 100 mg and 300 mg. In patients taking a single oral dose of 150 mg, the median tmax of Rezlidhia was approximately 4 hours. In healthy subjects, administration of a single dose (150 mg) of Rezlidhia during a high-fat meal (800-1000 calories, 50% of total dietary caloric content from fat) resulted in an increase in Cmax and AUCinf of 191% and 83%, respectively.

After Rezlidhia is approved for marketing, there is little information about its price and other related information. Please consult the medical consultant for details.